ライフサイエンスコーパス: chronic hepatitis

1 ymphocyte positioning in liver tissue during chronic hepatitis.

2 About 0.3% of all SIVH reported having chronic hepatitis.

3 for blocking carcinogenesis in patients with chronic hepatitis.

4 cause HBV persistence and the development of chronic hepatitis.

5 in human liver specimens from patients with chronic hepatitis.

6 BACKGROUND & AIMS: Chronic hepatitis affects phenotypes of innate and adapt

7 itis E virus (HEV) has emerged as a cause of chronic hepatitis among immunocompromised patients.

8 n 2 knockout (Mdr2(-/)) mice are a model for chronic hepatitis and inflammation-associated hepatocell

9 Eighty CHC patients (17 chronic hepatitis, and 63 cirrhosis) were enrolled.

10 The prognosis in severe acute flares of chronic hepatitis B (AFOCHB) is often unclear.

11 sponse to antiviral therapy in patients with chronic hepatitis B (CHB) , and to assess if these miRNA

12 Chronic hepatitis B (CHB) and nonalcoholic fatty liver d

13 Chronic hepatitis B (CHB) comorbidity data are limited.

14 Chronic hepatitis B (CHB) exhibits a variety of clinical

15 Chronic hepatitis B (CHB) has become a treatable and con

16 regulated gene transcripts in patients with chronic hepatitis B (CHB) in the absence of liver cirrho

17 Chronic hepatitis B (CHB) infection functional cure is d

18 ildren, but overall population prevalence of chronic hepatitis B (CHB) infection remains high.

19 Despite the high global prevalence of chronic hepatitis B (CHB) infection, datasets covering t

20 has been difficult to study in patients with chronic hepatitis B (CHB) infection.

21 r cirrhosis and/or hepatocellular carcinoma, chronic hepatitis B (CHB) is a major health problem.

22 Chronic hepatitis B (CHB) is a significant global health

23 Chronic hepatitis B (CHB) is associated with a dysfuncti

24 Chronic hepatitis B (CHB) is characterized by hepatic in

25 Antiviral therapy for chronic hepatitis B (CHB) is effective and can substanti

26 Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-

27 y of interferon alpha (IFNalpha) therapy for chronic hepatitis B (CHB) patients is about 40% and ofte

28 that the responses to IFN-alpha treatment of chronic hepatitis B (CHB) patients is influenced by IFN-

29 from healthy donors exposed to IFN-alpha and chronic hepatitis B (CHB) patients starting IFN-alpha th

30 Th9 and Th17 cells were quantified in chronic hepatitis B (CHB) patients with hepatic fibrosis

31 of developing liver cancer and cirrhosis in chronic hepatitis B (CHB) patients.

32 B surface antigen (HBsAg) turnover rates in chronic hepatitis B (CHB) patients.

33 Children with immune-tolerant features of chronic hepatitis B (CHB) received entecavir once-daily

34 f an electronic health record (EHR) alert on chronic hepatitis B (CHB) screening among at-risk Asian

35 Patients with chronic hepatitis B (CHB) usually acquire the virus peri

36 Globally, one third of prevalent chronic hepatitis B (CHB) virus infection (HBV) occurred

37 Treatment of patients with chronic hepatitis B (CHB) with nucleos(t)ide analogues (

38 tive therapeutic target for the treatment of chronic hepatitis B (CHB), but it is challenging to stud

39 The incidences of chronic hepatitis B (CHB), Hepatitis B virus (HBV)-assoc

40 t)ide analog (NA) treatment in patients with chronic hepatitis B (CHB).

41 ctive factors against disease progression in chronic hepatitis B (CHB).

42 figure may underestimate true mortality from chronic hepatitis B (CHB).

43 role in control of viral replication during chronic hepatitis B (cHBV) infection, but little is know

44 ay mortality than noncirrhotic patients with chronic hepatitis B [4.4% vs 1.3%, adjusted odds ratio (

45 Chronic hepatitis B affects over 300 million people who

46 ent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation.

47 s to achieve a 90% reduction in new cases of chronic hepatitis B and C and a 65% reduction in mortali

48 lly to treat other viral infections, such as chronic hepatitis B and C in humans.

49 Chronic hepatitis B and C viral infections are major ris

50 ptibility and pathogenesis in the setting of chronic hepatitis B and C.

51 in serum samples from patients with acute vs chronic hepatitis B and controls.

52 Chronic hepatitis B and D infections are major causes of

53 r carcinoma (HCC) and current treatments for chronic hepatitis B and HCC are suboptimal.

54 global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections.

55 Chronic hepatitis B develops more frequently in countrie

56 be used to guide management of patients with chronic hepatitis B due to high rates of misclassificati

57 regimen that can induce a functional cure of chronic hepatitis B in a small, but significant, fractio

58 vels in serum were elevated in patients with chronic hepatitis B infection (CHB) and acute-on-chronic

59 Chronic hepatitis B infection (HBV) is major cause of mo

60 Chronic hepatitis B infection affects >300 million peopl

61 th cirrhosis, 864 noncirrhotic controls with chronic hepatitis B infection, and 5468 noncirrhotic con

62 suggest immunotherapeutic strategies against chronic hepatitis B infection.

63 ope for treating adolescents and adults with chronic hepatitis B infection.

64 iviral agent entecavir was commenced for his chronic hepatitis B infection.

65 of high genetic barrier for the treatment of chronic hepatitis B infection.

66 Chronic hepatitis B is caused by prolonged infection wit

67 ned the long-term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated

68 cination.IMPORTANCE A curative treatment for chronic hepatitis B must eliminate the virus from the li

69 he introduction of these novel compounds for chronic hepatitis B necessitates a standardized appraisa

70 People with chronic hepatitis B or C infection, or both, and those w

71 l chronic inflammatory liver diseases, e.g., chronic hepatitis B or C viral infection and steatohepat

72 ar carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.

73 rom patients with acute hepatitis B, but not chronic hepatitis B or controls, hepatocytes expressed A

74 ified all adults who received a diagnosis of chronic hepatitis B or hepatitis C from 2005 through 201

75 nd gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection.

76 ff-treatment nucleos(t)ide analogues (NA) in chronic hepatitis B patients (CHB) is unclear.

77 nd CD4+ T cells from healthy donors and from chronic hepatitis B patients became polyfunctional effec

78 hepatocellular carcinoma (HCC) incidence in chronic hepatitis B patients under long-term therapy wit

79 lone without hepatitis B immune globulin for chronic hepatitis B patients with preexisting lamivudine

80 Fifty-seven consecutive chronic hepatitis B patients with preexisting rt204 LAM-

81 cohort study included 1,951 adult Caucasian chronic hepatitis B patients without HCC at baseline who

82 eyond year 5 of ETV/TDF therapy in Caucasian chronic hepatitis B patients, particularly in those with

83 i-fibrotic activity compared with those from chronic hepatitis B patients, which were mainly mediated

84 he majority of persons currently treated for chronic hepatitis B require long-term or lifelong therap

85 is a clinical indicator of poor outcome for chronic hepatitis B viral (HBV) infection.

86 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (H

87 graphic characteristics and comorbidities to chronic hepatitis B virus (HBV) controls using propensit

88 Rare individuals can naturally clear chronic hepatitis B virus (HBV) infection and acquire pr

89 Therapies for chronic hepatitis B virus (HBV) infection are urgently n

90 d in antiviral treatment-naive patients with chronic hepatitis B virus (HBV) infection but not in tre

91 ference (RNAi)-based therapeutic ARC-520 for chronic hepatitis B virus (HBV) infection consists of a

92 causes resistance to IFN therapy.IMPORTANCE Chronic hepatitis B virus (HBV) infection continues to b

93 he two drugs in patients with HBeAg-negative chronic hepatitis B virus (HBV) infection in a non-infer

94 he two drugs in patients with HBeAg-positive chronic hepatitis B virus (HBV) infection in a non-infer

95 Chronic hepatitis B virus (HBV) infection is a global pu

96 Chronic hepatitis B virus (HBV) infection is a global pu

97 Chronic hepatitis B virus (HBV) infection is a global pu

98 Chronic hepatitis B virus (HBV) infection is a major pub

99 Chronic hepatitis B virus (HBV) infection is a major ris

100 Chronic hepatitis B virus (HBV) infection is a major ris

101 Chronic hepatitis B virus (HBV) infection is a risk fact

102 Chronic hepatitis B virus (HBV) infection is estimated t

103 Chronic Hepatitis B Virus (HBV) infection is generally n

104 Chronic hepatitis B virus (HBV) infection is partly resp

105 A hallmark of chronic hepatitis B virus (HBV) infection is the functio

106 Chronic hepatitis B virus (HBV) infection often develop

107 The heterogeneous clinical courses of chronic hepatitis B virus (HBV) infection reflect the co

108 t strategy for children with immune-tolerant chronic hepatitis B virus (HBV) infection remains unknow

109 (known as functional cure) in patients with chronic hepatitis B virus (HBV) infection significantly

110 Vaccine failure with chronic hepatitis B virus (HBV) infection still develops

111 ican nations have among the highest rates of chronic hepatitis B virus (HBV) infection worldwide, but

112 There are 257 million persons worldwide with chronic hepatitis B virus (HBV) infection, a leading cau

113 Although there is no effective cure for chronic hepatitis B virus (HBV) infection, antibodies ar

114 lular carcinoma (HCC), often associated with chronic hepatitis B virus (HBV) infection.

115 and linkage to care can reduce the burden of chronic hepatitis B virus (HBV) infection.

116 nfections and are particularly promising for chronic hepatitis B virus (HBV) infection.

117 component of a treatment regimen for curing chronic hepatitis B virus (HBV) infection.

118 ded during the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection.

119 rn of hepatitis B surface antigen (HBsAg) in chronic hepatitis B virus (HBV) infections of China rema

120 Chronic hepatitis B virus (HBV) infections result in 887

121 and 2013, we identified 35,356 patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HC

122 ) in low-replicative (HBV DNA <20,000 IU/mL) chronic hepatitis B virus (HBV) patients.

123 the primary goal of developing agreement on chronic hepatitis B virus (HBV) treatment endpoints to g

124 Chronic hepatitis B virus (HBV), hepatitis C virus (HCV)

125 ediated disturbance of Mg(2+) homeostasis on chronic hepatitis B virus (HBV)-infected natural killer

126 onse is compatible with acute, resolved, and chronic hepatitis B virus (HBV)infection but might also

127 Chronic hepatitis B virus carriers are at risk of develo

128 European guidelines recommend treatment of chronic hepatitis B virus infection (CHB) with the nucle

129 Currently 247 million people are living with chronic hepatitis B virus infection (CHB), and the devel

130 nisms of immune dysfunction in patients with chronic hepatitis B virus infection, immunotherapy strat

131 us-specific T-cell immunity in patients with chronic hepatitis B virus infection.

132 Fewer than 1% of chronic hepatitis B virus infections per year are cured

133 Chronic hepatitis B virus or hepatitis C co-infection wa

134 hypertension, type 2 diabetes mellitus, and chronic hepatitis B with cirrhosis presented with a 2-we

135 Patients were divided into three groups: chronic hepatitis B without cirrhosis; HBV-related cirrh

136 analogue treatment exists for patients with chronic hepatitis B, although treatment is generally ant

137 There is no definite cure for chronic hepatitis B, and alpha interferon (IFN-alpha) is

138 ablish a persistent infection in people with chronic hepatitis B, leading to accelerated progression

139 In patients with chronic hepatitis B, TAF appears to be as effective as T

140 reactivation after liver transplantation for chronic hepatitis B, with a durable HBsAg seroclearance

141 ferent disease phases of young patients with chronic hepatitis B, with emphasis on the so-called immu

142 ising therapeutic option in the treatment of chronic hepatitis B, with our lead candidate now enterin

143 during the natural history and treatment of chronic hepatitis B.

144 during the natural history and treatment of chronic hepatitis B.

145 cirrhosis is important for the management of chronic hepatitis B.

146 and foreseeable therapeutic developments in chronic hepatitis B.

147 ay be a good alternative to TDF for treating chronic hepatitis B.

148 sign of curative antiviral therapies against chronic hepatitis B.

149 diseases, which may open a new venue to cure chronic hepatitis B.

150 cination strategy for the functional cure of chronic hepatitis B.

151 foreign-born African Americans (FBAAs) with chronic hepatitis B.

152 on of antiviral therapeutics for the cure of chronic hepatitis B.

153 f serum samples from patients with acute and chronic hepatitis B.

154 of off-NA VR in patients with HBeAg-negative chronic hepatitis B.

155 in clinical development for the treatment of chronic hepatitis B.

156 inical trials aiming at a functional cure of chronic hepatitis B.

157 to accelerating the discovery of a cure for chronic hepatitis B.

158 H0731 doses up to 300 mg in individuals with chronic hepatitis B.

159 cellular enzymes may facilitate the cure of chronic hepatitis B.IMPORTANCE Persistent HBV infection

160 As a positive control, transmission of chronic hepatitis before and after implementation of hep

161 Here, we demonstrate in 1689 patients with chronic hepatitis C (CHC) (1,501 with CHC and 188 with H

162 mproving prediction of treatment outcomes in chronic hepatitis C (CHC) genotype 4 (G4) is necessary t

163 In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a

164 proving hepatic fibrosis and inflammation in chronic hepatitis C (CHC) patients after eradication wit

165 istribution and liver disease progression in chronic hepatitis C (CHC) patients with T2D.

166 supplementation on serum fibrotic markers in chronic hepatitis C (CHC) patients.

167 es in metabolic and inflammatory outcomes in chronic hepatitis C (CHC) patients: low-density lipoprot

168 pe of hepatitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication f

169 about mortality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited.

170 play important roles in the pathogenesis of chronic hepatitis C (CHC).

171 Patients with chronic hepatitis C (HCV) infection have high prevalence

172 liver damage, especially in individuals with chronic hepatitis C (HCV); however, the impact of nonhea

173 ng the use of direct-acting agents (DAAs) in chronic hepatitis C [2].

174 This study included 252 patients with chronic hepatitis C and 150 healthy volunteers.

175 onsistent with these findings, patients with chronic hepatitis C and nonalcoholic steatohepatitis sig

176 % credible interval 30-44), the incidence of chronic hepatitis C by 37% (29-44), and chronic hepatiti

177 atments have reduced the prevalence of adult chronic hepatitis C by a median 37% (95% credible interv

178 Chronic hepatitis C can result in progressive liver dise

179 ong the estimated 150 000 adults living with chronic hepatitis C in Georgia, 52 856 (35.1%) were diag

180 Among estimated 150,000 adults living with chronic hepatitis C in Georgia, 52,856 (35.1%) were diag

181 ould suggest a secondary Mooren ulcer, but a chronic hepatitis C infection was detected.

182 of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results

183 eks is highly effective for the treatment of chronic hepatitis C infection.

184 ith sickle cell disease are at high risk for chronic hepatitis C infection.

185 diseased livers explanted from patients with chronic hepatitis C infection.

186 e of chronic hepatitis C by 37% (29-44), and chronic hepatitis C mortality by 14% (3-30) and have pre

187 mbined cohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121

188 The treatment of chronic hepatitis C patients before they developed cirrh

189 This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment e

190 atosteatosis, a common pathology observed in chronic hepatitis C patients.

191 ions' recommendations that all patients with chronic hepatitis C should be treated.

192 rus (HCV) is essential for the management of chronic hepatitis C therapy.

193 e been reported in liver transplantation and chronic hepatitis C treatment outcomes.

194 Among treatment-naive individuals with chronic hepatitis C viral (HCV) infection and without ci

195 Chronic hepatitis C viral (HCV) infection has been assoc

196 ith hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

197 ced hepatocellular carcinoma and concomitant chronic hepatitis C viral infection.

198 Many patients with chronic hepatitis C virus (HCV) are on prolonged proton-

199 efficacy and safety in a phase IIa study in chronic hepatitis C virus (HCV) genotype (GT)-1-infected

200 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

201 proved in the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infecti

202 lated with pibrentasvir is approved to treat chronic hepatitis C virus (HCV) genotype 1-6 infection i

203 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rat

204 rect-acting antiviral agents that can cure a chronic hepatitis C virus (HCV) infection after 8-12 wee

205 Treatment of chronic hepatitis C virus (HCV) infection after renal al

206 ng evidence indicates an association between chronic hepatitis C virus (HCV) infection and B-cell lym

207 s is a frequent complication associated with chronic hepatitis C virus (HCV) infection and is a key p

208 previr regimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5

209 ole of MAIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate

210 trials have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC

211 Chronic hepatitis C virus (HCV) infection causes decreas

212 An unbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the i

213 Whether chronic hepatitis C virus (HCV) infection decreases humo

214 direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstra

215 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rate

216 Chronic hepatitis C virus (HCV) infection in Asia is cha

217 Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

218 nd: Use of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney tran

219 Most persons with chronic hepatitis C virus (HCV) infection in the United

220 herapy can safely prevent the development of chronic hepatitis C virus (HCV) infection in uninfected

221 Liver disease as a result of chronic hepatitis C virus (HCV) infection is a global pr

222 Chronic hepatitis C virus (HCV) infection is a leading c

223 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major bur

224 , interferon-alpha (IFN-alpha) treatment for chronic hepatitis C virus (HCV) infection is an ideal mo

225 Chronic hepatitis C virus (HCV) infection is associated

226 Chronic hepatitis C virus (HCV) infection is characteriz

227 Chronic hepatitis C virus (HCV) infection is characteriz

228 The efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined

229 Chronic hepatitis C virus (HCV) infection is more preval

230 Chronic hepatitis C virus (HCV) infection is one of the

231 The mechanism of how chronic hepatitis C virus (HCV) infection leads to such

232 th human immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescri

233 Untreated, chronic hepatitis C virus (HCV) infection may lead to pr

234 In Egypt, chronic hepatitis C virus (HCV) infection occurs in arou

235 The immuno-pathogenic mechanisms of chronic hepatitis C virus (HCV) infection remain to be e

236 Diagnosis of chronic hepatitis C virus (HCV) infection requires both

237 Chronic hepatitis C virus (HCV) infection with advanced

238 ee, complete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrho

239 ting antivirals (DAAs) effectively eradicate chronic hepatitis C virus (HCV) infection, although HCV

240 Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the

241 to a high cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this stil

242 For children under 12 years of age who have chronic hepatitis C virus (HCV) infection, there are cur

243 course of direct-acting antiviral agents for chronic hepatitis C virus (HCV) infection, we examined t

244 ect-acting antivirals (DAA) for treatment of chronic hepatitis C virus (HCV) infection, we looked at

245 Chronic hepatitis C virus (HCV) infection-associated liv

246 CD4+ T cell failure is a hallmark of chronic hepatitis C virus (HCV) infection.

247 ents of treatment regimens for patients with chronic hepatitis C virus (HCV) infection.

248 ) play a central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.

249 egimens have been approved for children with chronic hepatitis C virus (HCV) infection.

250 f viral eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.

251 All patients with chronic hepatitis C virus (HCV) infections can and shoul

252 The mechanisms of chronic hepatitis C virus (HCV)-induced liver fibrosis a

253 the risk of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and th

254 We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% h

255 e who inject drugs in the United States have chronic hepatitis C virus (HCV).

256 evir + TMC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatm

257 ment for 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.

258 afe and highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.

259 ns with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant reci

260 Children with chronic hepatitis C virus infection have limited treatme

261 -acting antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortali

262 pulations after DAA therapy in patients with chronic hepatitis C virus infection in the context of th

263 Chronic hepatitis C virus infection is associated with s

264 Chronic hepatitis C virus infection is well-recognized a

265 ffective and well tolerated in patients with chronic hepatitis C virus infection, including those wit

266 nse (SVR) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race

267 ent has revolutionized care of patients with chronic hepatitis C virus infection.

268 recommendations on the care of patients with chronic hepatitis C virus who have achieved SVR.

269 atocellular carcinoma (HCC) in patients with chronic hepatitis C virus; however, their impact in pati

270 s B vaccination among patients in China with chronic hepatitis C who are not in treatment.

271 Despite effective treatment for chronic hepatitis C, deficiencies in diagnosis and acces

272 wo cases of HBV reactivation and one case of chronic hepatitis C, which were successfully treated.

273 udy, we elucidate the potential link between chronic hepatitis C-associated inflammation and alterati

274 ts for prevention of hepatocarcinogenesis in chronic hepatitis C.

275 nt scale-up, which has reduced the burden of chronic hepatitis C.

276 and averted 252 (134-389) deaths related to chronic hepatitis C.

277 s patient-reported outcomes in patients with chronic hepatitis C.

278 Chronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liv

279 ost infected patients, and eventually causes chronic hepatitis, cirrhosis, and hepatocellular carcino

280 analyzed data from CHB patients seen in the Chronic Hepatitis Cohort Study (CHeCS) between 1 January

281 Chronic hepatitis delta virus (HDV) infection causes sev

282 s the need for new treatment options to cure chronic hepatitis E in the setting of organ transplantat

283 Chronic hepatitis E represents an emerging challenge in

284 t ribavirin is highly efficient for treating chronic hepatitis E virus (HEV) infection and shows that

285 Chronic hepatitis E virus (HEV) infection is a significa

286 avirin is currently recommended for treating chronic hepatitis E virus (HEV) infection.

287 Antiviral treatment options for chronic Hepatitis E Virus (HEV) infections are limited a

288 in developing effective therapeutics against chronic hepatitis E.

289 nt with decompensated graft cirrhosis due to chronic hepatitis E.

290 HBV causes chronic hepatitis, fibrosis, cirrhosis, and hepatocellul

291 h hepatitis E virus genotype 3 may result in chronic hepatitis in immunocompromised patients.

292 Liver fibrosis can regress in patients with chronic hepatitis in whom the underlying cause of liver

293 ndetectable viral replication and absence of chronic hepatitis infection (n = 796) were recruited fro

294 lfa occurred in three (27%) patients (severe chronic hepatitis; moderate immediate post-injection rea

295 tolerance to hepatocellular Ags, leading to chronic hepatitis resembling human AIH type 1.

296 s C virus (HCV) have ushered in a new era in chronic hepatitis treatment.

297 ients with HBeAg-positive and HBeAg-negative chronic hepatitis, treatment-naive or virally suppressed

298 r carcinomas (HCCs) develop in patients with chronic hepatitis, which creates a microenvironment for

299 irus (HCV) infection is the leading cause of chronic hepatitis, which often results in liver fibrosis

300 trast, HBV-infected HIS-HUHEP mice developed chronic hepatitis with 10-fold lower titers and antigen-